> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Supernus Convertible Notes Now Convert Into 30.9355 Shares Per $1,000, Up From 24.0033
- URL: https://www.bullished.co/supernus-convertible-notes-now-convert-into-30-9355-shares-per-1-000-up-from-24-0033-e87f0ff6/
- Published: 2026-11-03T14:21:10.000Z
- Updated: 2026-11-03T14:21:10.000Z
- Description: The special dividend triggers the adjustment, which sets a conversion price of about $32.33 per share, the company said.
- Author: Matteo Parrino
- Tags: Earnings, SUPN, Industry: Healthcare

[Supernus](https://www.bullished.co/tag/indv/) raised the conversion rate on its 0.625% convertible notes due 2031 to [30.9355 shares](https://www.sec.gov/Archives/edgar/data/0001625297/000162529726000030/indv-20261103.htm?ref=bullished.co) per $1,000 of principal, from 24.0033, the company said in an [8-K](https://www.bullished.co/learn/8-k-items-explained/) filed Tuesday. The change follows the special dividend its board declared on September 16, 2026.

## A lower price to convert

The new rate reflects a [conversion price of approximately $32.33](https://www.sec.gov/Archives/edgar/data/0001625297/000162529726000030/indv-20261103.htm?ref=bullished.co) per share, according to the filing. Each $1,000 note can now be swapped for about 6.9 more shares than before the adjustment.

The notes are the company's 0.625% Convertible Senior Notes due 2031, issued under an indenture dated March 17, 2026 with U.S. Bank Trust Company, National Association. The indenture, which the filing describes as governing the notes, required the change after the special dividend. The company is formerly known as Indivior Pharmaceuticals, Inc.

No bondholders converted their bonds into common stock, the company said.

## Shares sit above the conversion price

The stock closed at $36.28 on Monday, above the $32.33 conversion price. A holder who converted at that price would receive shares worth more than the notes' face value, though the filing reports no conversions.

The filing says the conversion rate stays subject to customary adjustments under the indenture when certain events occur.

## The business behind the notes

The company, listed as INDV in our records, develops prescription medicines for opioid use disorder. Its core products are Sublocade, a monthly buprenorphine injection, and Suboxone Film, which dissolves under the tongue or inside the cheek. The US accounted for 85% of net revenues for the year ended December 31, 2025, according to its annual report.

Any further change to the rate would come only from the events the indenture lists as triggers for adjustment.

Learn

- [Item 8.01: other events →](https://www.bullished.co/learn/8-k-items-explained/#item-801-other-events)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Supernus, Inc. (INDV)](https://www.sec.gov/Archives/edgar/data/0001625297/000162529726000030/indv-20261103.htm?ref=bullished.co) — SEC EDGAR

### More on Indivior

- [Indivior's $488 Million Convertible Debt Turns Current Ahead Of $1 Billion Special Dividend](https://www.bullished.co/indiviors-488-million-convertible-debt-turns-current-ahead-of-1-billion-special-dividend-a7410f90/)
- [Indivior's Quarterly Profit Hits Record $137 Million Days Before Supernus Merger Is Set To Close](https://www.bullished.co/indiviors-quarterly-profit-hits-record-137-million-days-before-supernus-merger-is-set-to-e4e14516/)
- [Indivior And Supernus Add Cantor Valuation Detail To Merger Proxy, Denying Any Disclosure Was Required](https://www.bullished.co/indivior-and-supernus-add-cantor-valuation-detail-to-merger-proxy-denying-any-disclosure-6e50827c/)

[All Indivior (INDV) coverage →](https://www.bullished.co/tag/indv/)